Clinical Trials & Pipeline
Mirna is a biopharmaceutical company focused on microRNA-based oncology therapeutics.
LEARN MORE ABOUT US
MRX34, Mirna’s first product candidate, was the first microRNA mimic to enter clinical testing.
March 14, 2017
Mirna Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016
November 10, 2016
Mirna Reports Third Quarter 2016 Financial Results and MRX34 Clinical Program Updates
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.